Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

In vitro characterization of the thermoneutral transient receptor potential vanilloid-1 (TRPV1) inhibitor GRTE16523.

Damann N, Bahrenberg G, Stockhausen H, Habermann CJ, Lesch B, Frank-Foltyn R, Lee J, Ann J, Christoph T.

Eur J Pharmacol. 2020 Mar 15;871:172934. doi: 10.1016/j.ejphar.2020.172934. Epub 2020 Jan 16.

PMID:
31954706
2.

Discovery of indane propanamides as potent and selective TRPV1 antagonists.

Ahn S, Kim YS, Kim MS, Ann J, Ha H, Yoo YD, Kim YH, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Stockhausen H, Christoph T, Lee J.

Bioorg Med Chem Lett. 2020 Feb 1;30(3):126838. doi: 10.1016/j.bmcl.2019.126838. Epub 2019 Dec 3.

PMID:
31864799
3.

Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors.

Alen J, Schade M, Wagener M, Christian F, Nordhoff S, Merla B, Dunkern TR, Bahrenberg G, Ratcliffe P.

J Med Chem. 2019 Jul 11;62(13):6391-6397. doi: 10.1021/acs.jmedchem.9b00218. Epub 2019 Jun 25.

PMID:
31244106
4.

Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.

Pletinckx K, Vaßen S, Schlusche I, Nordhoff S, Bahrenberg G, Dunkern TR.

Pharmacol Res Perspect. 2019 Jun 18;7(4):e00482. doi: 10.1002/prp2.482. eCollection 2019 Aug.

5.

4-Aminophenyl acetamides and propanamides as potent transient receptor potential vanilloid 1 (TRPV1) ligands.

Kim C, Ann J, Lee S, Kim E, Choi S, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Stockhausen H, Christoph T, Lee J.

Bioorg Med Chem. 2018 Aug 15;26(15):4509-4517. doi: 10.1016/j.bmc.2018.07.040. Epub 2018 Jul 25.

PMID:
30078610
6.

Discovery of 2-(3,5-difluoro-4-methylsulfonaminophenyl)propanamides as potent TRPV1 antagonists.

Kim C, Ann J, Lee S, Sun W, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Stockhausen H, Christoph T, Lee J.

Bioorg Med Chem Lett. 2018 Aug 1;28(14):2539-2542. doi: 10.1016/j.bmcl.2018.05.043. Epub 2018 May 23.

PMID:
29884534
7.

RNA interference-based functional knockdown of the voltage-gated potassium channel Kv7.2 in dorsal root ganglion neurons after in vitro and in vivo gene transfer by adeno-associated virus vectors.

Valdor M, Wagner A, Röhrs V, Berg J, Fechner H, Schröder W, Tzschentke TM, Bahrenberg G, Christoph T, Kurreck J.

Mol Pain. 2018 Jan-Dec;14:1744806917749669. doi: 10.1177/1744806917749669. Epub 2017 Dec 6.

8.

Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists.

Lee S, Kim C, Ann J, Thorat SA, Kim E, Park J, Choi S, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Stockhausen H, Christoph T, Lee J.

Bioorg Med Chem Lett. 2017 Sep 15;27(18):4383-4388. doi: 10.1016/j.bmcl.2017.08.020. Epub 2017 Aug 12.

9.

t-Butyl pyridine and phenyl C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists.

Lee S, Kang DW, Ryu H, Kim C, Ann J, Lee H, Kim E, Hong S, Choi S, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Stockhausen H, Christoph T, Lee J.

Bioorg Med Chem. 2017 Apr 15;25(8):2451-2462. doi: 10.1016/j.bmc.2017.03.004. Epub 2017 Mar 6.

10.

Novel Function of Serine Protease HTRA1 in Inhibiting Adipogenic Differentiation of Human Mesenchymal Stem Cells via MAP Kinase-Mediated MMP Upregulation.

Tiaden AN, Bahrenberg G, Mirsaidi A, Glanz S, Blüher M, Richards PJ.

Stem Cells. 2016 Jun;34(6):1601-14. doi: 10.1002/stem.2297. Epub 2016 Feb 16.

11.

Structure activity relationships of benzyl C-region analogs of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides as potent TRPV1 antagonists.

Ann J, Jung A, Kim MY, Kim HM, Ryu H, Kim S, Kang DW, Hong S, Cui M, Choi S, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Stockhausen H, Christoph T, Lee J.

Bioorg Med Chem. 2015 Nov 1;23(21):6844-54. doi: 10.1016/j.bmc.2015.10.001. Epub 2015 Oct 9.

12.

Use of biomimetic microtissue spheroids and specific growth factor supplementation to improve tenocyte differentiation and adaptation to a collagen-based scaffold in vitro.

Theiss F, Mirsaidi A, Mhanna R, Kümmerle J, Glanz S, Bahrenberg G, Tiaden AN, Richards PJ.

Biomaterials. 2015 Nov;69:99-109. doi: 10.1016/j.biomaterials.2015.08.013. Epub 2015 Aug 10.

PMID:
26283157
13.

α-Substituted 2-(3-fluoro-4-methylsulfonamidophenyl)acetamides as potent TRPV1 antagonists.

Tran PT, Kim HS, Ann J, Kim SE, Kim C, Hong M, Hoang VH, Ngo VT, Hong S, Cui M, Choi S, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Stockhausen H, Christoph T, Lee J.

Bioorg Med Chem Lett. 2015 Jun 1;25(11):2326-30. doi: 10.1016/j.bmcl.2015.04.024. Epub 2015 Apr 12.

14.

Pyridine C-region analogs of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists.

Ryu H, Seo S, Lee JY, Ha TH, Lee S, Jung A, Ann J, Kim SE, Yoon S, Hong M, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Schiene K, Stockhausen H, Christoph T, Frormann S, Lee J.

Eur J Med Chem. 2015 Mar 26;93:101-8. doi: 10.1016/j.ejmech.2015.02.001. Epub 2015 Feb 2.

15.

6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists.

Sun W, Kim HS, Lee S, Jung A, Kim SE, Ann J, Yoon S, Choi S, Lee JH, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Schiene K, Stockhausen H, Christoph T, Frormann S, Lee J.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):803-6. doi: 10.1016/j.bmcl.2014.12.086. Epub 2015 Jan 5.

PMID:
25597011
16.

2-Aryl substituted pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as highly potent TRPV1 antagonists.

Ryu H, Seo S, Kim MS, Kim MY, Kim HS, Ann J, Tran PT, Hoang VH, Byun J, Cui M, Son K, Sharma PK, Choi S, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Koegel BY, Christoph T, Frormann S, Lee J.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):4044-7. doi: 10.1016/j.bmcl.2014.05.072. Epub 2014 Jun 2.

17.

2-Alkyl/alkenyl substituted pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as highly potent TRPV1 antagonists.

Ryu H, Seo S, Cho SH, Kim HS, Jung A, Kang DW, Son K, Cui M, Hong SH, Sharma PK, Choi S, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Stockhausen H, Schiene K, Christoph T, Frormann S, Lee J.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):4039-43. doi: 10.1016/j.bmcl.2014.05.074. Epub 2014 Jun 2.

18.

A hydrophobic residue in position 15 of the rP2X3 receptor slows desensitization and reveals properties beneficial for pharmacological analysis and high-throughput screening.

Hausmann R, Bahrenberg G, Kuhlmann D, Schumacher M, Braam U, Bieler D, Schlusche I, Schmalzing G.

Neuropharmacology. 2014 Apr;79:603-15. doi: 10.1016/j.neuropharm.2014.01.010. Epub 2014 Jan 19.

PMID:
24452010
19.

TRPV1 antagonist with high analgesic efficacy: 2-Thio pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides.

Ha TH, Ryu H, Kim SE, Kim HS, Ann J, Tran PT, Hoang VH, Son K, Cui M, Choi S, Blumberg PM, Frank R, Bahrenberg G, Schiene K, Christoph T, Frormann S, Lee J.

Bioorg Med Chem. 2013 Nov 1;21(21):6657-64. doi: 10.1016/j.bmc.2013.08.015. Epub 2013 Aug 13.

20.

Assessment of the matrix degenerative effects of MMP-3, ADAMTS-4, and HTRA1, injected into a bovine intervertebral disc organ culture model.

Furtwängler T, Chan SC, Bahrenberg G, Richards PJ, Gantenbein-Ritter B.

Spine (Phila Pa 1976). 2013 Oct 15;38(22):E1377-87. doi: 10.1097/BRS.0b013e31829ffde8.

21.

2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists: structure activity relationships of the 2-oxy pyridine C-region.

Thorat SA, Kang DW, Ryu H, Kim MS, Kim HS, Ann J, Ha T, Kim SE, Son K, Choi S, Blumberg PM, Frank R, Bahrenberg G, Schiene K, Christoph T, Lee J.

Eur J Med Chem. 2013 Jun;64:589-602. doi: 10.1016/j.ejmech.2013.04.003. Epub 2013 Apr 11.

22.

Salt bridge switching from Arg290/Glu167 to Arg290/ATP promotes the closed-to-open transition of the P2X2 receptor.

Hausmann R, Günther J, Kless A, Kuhlmann D, Kassack MU, Bahrenberg G, Markwardt F, Schmalzing G.

Mol Pharmacol. 2013 Jan;83(1):73-84. doi: 10.1124/mol.112.081489. Epub 2012 Oct 5.

PMID:
23041661
23.

2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-region.

Kim MS, Ryu H, Kang DW, Cho SH, Seo S, Park YS, Kim MY, Kwak EJ, Kim YS, Bhondwe RS, Kim HS, Park SG, Son K, Choi S, DeAndrea-Lazarus IA, Pearce LV, Blumberg PM, Frank R, Bahrenberg G, Stockhausen H, Kögel BY, Schiene K, Christoph T, Lee J.

J Med Chem. 2012 Oct 11;55(19):8392-408. doi: 10.1021/jm300780p. Epub 2012 Sep 20.

24.

Human serine protease HTRA1 positively regulates osteogenesis of human bone marrow-derived mesenchymal stem cells and mineralization of differentiating bone-forming cells through the modulation of extracellular matrix protein.

Tiaden AN, Breiden M, Mirsaidi A, Weber FA, Bahrenberg G, Glanz S, Cinelli P, Ehrmann M, Richards PJ.

Stem Cells. 2012 Oct;30(10):2271-82. doi: 10.1002/stem.1190.

25.

Detrimental role for human high temperature requirement serine protease A1 (HTRA1) in the pathogenesis of intervertebral disc (IVD) degeneration.

Tiaden AN, Klawitter M, Lux V, Mirsaidi A, Bahrenberg G, Glanz S, Quero L, Liebscher T, Wuertz K, Ehrmann M, Richards PJ.

J Biol Chem. 2012 Jun 15;287(25):21335-45. doi: 10.1074/jbc.M112.341032. Epub 2012 May 3.

26.

Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking.

Wolf C, Rosefort C, Fallah G, Kassack MU, Hamacher A, Bodnar M, Wang H, Illes P, Kless A, Bahrenberg G, Schmalzing G, Hausmann R.

Mol Pharmacol. 2011 Apr;79(4):649-61. doi: 10.1124/mol.110.068700. Epub 2010 Dec 29.

PMID:
21191044
27.

Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice.

Christoph T, Bahrenberg G, De Vry J, Englberger W, Erdmann VA, Frech M, Kögel B, Röhl T, Schiene K, Schröder W, Seibler J, Kurreck J.

Mol Cell Neurosci. 2008 Mar;37(3):579-89. doi: 10.1016/j.mcn.2007.12.006. Epub 2007 Dec 15.

PMID:
18249134
28.

Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1.

Christoph T, Gillen C, Mika J, Grünweller A, Schäfer MK, Schiene K, Frank R, Jostock R, Bahrenberg G, Weihe E, Erdmann VA, Kurreck J.

Neurochem Int. 2007 Jan;50(1):281-90. Epub 2006 Oct 12.

PMID:
17045702
29.

A new class of Spiegelmers containing 2'-fluoro-nucleotides.

Helmling S, Moyroud E, Schroeder W, Roehl I, Kleinjung F, Stark S, Bahrenberg G, Gillen C, Klussmann S, Vonhoff S.

Nucleosides Nucleotides Nucleic Acids. 2003 May-Aug;22(5-8):1035-8.

PMID:
14565337
30.

Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism.

Kortylewski M, Feld F, Krüger KD, Bahrenberg G, Roth RA, Joost HG, Heinrich PC, Behrmann I, Barthel A.

J Biol Chem. 2003 Feb 14;278(7):5242-9. Epub 2002 Nov 26.

31.
32.

Differential regulation of endogenous glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression by the forkhead transcription factor FKHR in H4IIE-hepatoma cells.

Barthel A, Schmoll D, Krüger KD, Bahrenberg G, Walther R, Roth RA, Joost HG.

Biochem Biophys Res Commun. 2001 Jul 27;285(4):897-902.

PMID:
11467835
33.

PSCA expression is regulated by phorbol ester and cell adhesion in the bladder carcinoma cell line RT112.

Bahrenberg G, Brauers A, Joost HG, Jakse G.

Cancer Lett. 2001 Jul 10;168(1):37-43.

PMID:
11368875
34.
35.

Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors.

Bahrenberg G, Brauers A, Joost HG, Jakse G.

Biochem Biophys Res Commun. 2000 Sep 7;275(3):783-8.

PMID:
10973799
36.

GLUT8, a novel member of the sugar transport facilitator family with glucose transport activity.

Doege H, Schürmann A, Bahrenberg G, Brauers A, Joost HG.

J Biol Chem. 2000 May 26;275(21):16275-80.

37.

NADH: ubiquinone oxidoreductase in obligate aerobic yeasts.

Büschges R, Bahrenberg G, Zimmermann M, Wolf K.

Yeast. 1994 Apr;10(4):475-9.

PMID:
7941733

Supplemental Content

Loading ...
Support Center